You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -50.5% | -67.2% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -12.0 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 6.3 | 5.4 |
| Price / Book value | 8.8 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 19.2% | 8.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -6.8% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | 7.16 | -1.84 | $-15.18 | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2015-12-31 | 9.29 | -1.45 | $-1.86 | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2016-12-31 | 12.27 | -3.35 | $-0.11 | -15.4 | 0.0 | n/a | n/a | 0.0% |
| 2017-12-31 | 13.98 | -9.92 | $-0.20 | -16.3 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | 16.67 | -8.87 | $-0.17 | -14.2 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | 15.34 | -10.30 | -18.88p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-12-31 | 18.27 | -8.50 | -15.04p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| MaxCyte begins dosing second cohort in MCY-M11 clinical trial Sharecast News | 08 May |
|---|---|
| MaxCyte launches new generation of cellular engineering instruments Sharecast News | 08 Apr |
| MaxCyte buddies-up with Gilead subsidiary Sharecast News | 12 Nov |
| Second Price Monitoring Extn | 08-May-19 16:42 |
|---|---|
| Price Monitoring Extension | 08-May-19 16:37 |
| Phase I Clinical Trial of MCY-M11 Progressed | 08-May-19 07:04 |
| Final Results for Year Ended 31 December 2018 | 24-Apr-19 07:03 |
| Launch of ExPERTT Instrument Family | 08-Apr-19 07:03 |